Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Common Equity (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Common Equity data on record, last reported at -$26.9 million in Q3 2025.

  • For Q3 2025, Common Equity fell 254.61% year-over-year to -$26.9 million; the TTM value through Sep 2025 reached -$26.9 million, down 254.61%, while the annual FY2024 figure was $11.2 million, 63.76% down from the prior year.
  • Common Equity reached -$26.9 million in Q3 2025 per MBRX's latest filing, down from -$3.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $88.5 million in Q1 2021 and bottomed at -$26.9 million in Q3 2025.
  • Average Common Equity over 5 years is $41.7 million, with a median of $40.3 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 478.84% in 2021, then plummeted 254.61% in 2025.
  • A 5-year view of Common Equity shows it stood at $79.0 million in 2021, then tumbled by 33.93% to $52.2 million in 2022, then plummeted by 40.74% to $30.9 million in 2023, then tumbled by 63.76% to $11.2 million in 2024, then tumbled by 340.19% to -$26.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$26.9 million in Q3 2025, -$3.6 million in Q2 2025, and $13.8 million in Q1 2025.